Cell Surface Phenotype of Different EBV-Infected Transformed T-Cell Lines
. | CD2 . | CD3 . | TCR . | CD4 . | CD8 . | CD28 . | CD25 . | CD45RA . | CD45RO . | CD56 . | HLA-DR . | CD44 . |
---|---|---|---|---|---|---|---|---|---|---|---|---|
EBV 41 | 97 | 78 | 73 | 3 | 68 | 100 | 0 | 85 | 10 | 0 | 0 | 5 |
EBV 32 | 93 | 94 | 69 | 7 | 97 | 100 | 0 | 87 | 5 | 3 | 0 | 3 |
T1B5 | 99 | 92 | 94 | 0 | 87 | 100 | 6 | 89 | 7 | 0 | 0 | 6 |
TFS | 90 | 97 | 89 | 87 | 0 | 100 | 4 | 92 | 2 | 0 | 0 | 14 |
E1V | 85 | 81 | 97 | 47 | 0 | 100 | 0 | 87 | 6 | 0 | 0 | 10 |
2C8 | 99 | 95 | 79 | 94 | 0 | 100 | 5 | 93 | 7 | 2 | 0 | 6 |
2G4 | 95 | 97 | 91 | 94 | 0 | 100 | 12 | 96 | 9 | 3 | 0 | 5 |
2G8 | 96 | 94 | 42 | 67 | 4 | 100 | 0 | 99 | 7 | 4 | 0 | 0 |
NC5 | 98 | 99 | 96 | 3 | 98 | 100 | 2 | 97 | 10 | 3 | 0 | 3 |
TC | 100 | 98 | 95 | 9 | 94 | 100 | 6 | 89 | 9 | 0 | 0 | 9 |
. | CD2 . | CD3 . | TCR . | CD4 . | CD8 . | CD28 . | CD25 . | CD45RA . | CD45RO . | CD56 . | HLA-DR . | CD44 . |
---|---|---|---|---|---|---|---|---|---|---|---|---|
EBV 41 | 97 | 78 | 73 | 3 | 68 | 100 | 0 | 85 | 10 | 0 | 0 | 5 |
EBV 32 | 93 | 94 | 69 | 7 | 97 | 100 | 0 | 87 | 5 | 3 | 0 | 3 |
T1B5 | 99 | 92 | 94 | 0 | 87 | 100 | 6 | 89 | 7 | 0 | 0 | 6 |
TFS | 90 | 97 | 89 | 87 | 0 | 100 | 4 | 92 | 2 | 0 | 0 | 14 |
E1V | 85 | 81 | 97 | 47 | 0 | 100 | 0 | 87 | 6 | 0 | 0 | 10 |
2C8 | 99 | 95 | 79 | 94 | 0 | 100 | 5 | 93 | 7 | 2 | 0 | 6 |
2G4 | 95 | 97 | 91 | 94 | 0 | 100 | 12 | 96 | 9 | 3 | 0 | 5 |
2G8 | 96 | 94 | 42 | 67 | 4 | 100 | 0 | 99 | 7 | 4 | 0 | 0 |
NC5 | 98 | 99 | 96 | 3 | 98 | 100 | 2 | 97 | 10 | 3 | 0 | 3 |
TC | 100 | 98 | 95 | 9 | 94 | 100 | 6 | 89 | 9 | 0 | 0 | 9 |
Results are expressed as the percentage of positive cells. Cells were stained with saturating amounts of FITC- or PE-conjugated MoAbs (Becton Dickinson) and analyzed by using a cytofluometer (Epics; Becton Dickinson). EBV 41 and EBV 32 were isolated from donor 1; T1B5, TFS, and E1V from donor 2; 2C8, 2G4, and 2G8 and NC5 from donor 3. TC cells were isolated from a solid tumor in a RAG2-deficient after subcutaneous injection of NC5 cells.